Fig. 1 · Structure

Documents & Downloads

HPGDS inhibitor 1

Cat. No. A12258 CAS 1033836-12-2

HPGDS inhibitor

HPGDS inhibitor 1 is a novel and selective Hematopoietic Prostaglandin D Synthase (HPGDS) inhibitor with an IC50 Value of 0.7 nM.

In Stock

Publications for HPGDS inhibitor 1

1 publication citing this product

  1. Beixian Zhou, .et al. , Chin Med, 2023, Oct 27;18(1):139 PMID: 37891648

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

A cocrystal places compound 8 at the HPGDS active site, with pyridyl/Trp104 stacking and contacts involving water and glutathione. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cellular Effect

Cell Line Activity Value Description Reference
MEG-01 EC50 0.035 μM Inhibition HPGDS in human MEG01 cells assessed as reduction in PGD2 production incubated for 30 mins followed by stimulation with 5 uM ionomycin for 30 mins by enzyme immunoassay method [PMID: 25978964]

HPGDS inhibitor 1 Research Summary

This section summarizes 1 in vitro study and 1 in vivo study of HPGDS inhibitor 1 from 1 published reference. In vitro models include HPGDS–compound 8 cocrystal. In vivo models include antigen-responsive allergic sheep.

HPGDS inhibitor 1 In Vitro Studies

HPGDS cocrystal binding

Biochemical assay · HPGDS–compound 8 cocrystal [1]

Active-site binding includes pyridyl/Trp104 stacking and polar contacts involving water and glutathione.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cocrystal refinementResolution 2.1 Å[1]

Literature-Reported Treatment Conditions

Method
Crystal soaking
Co-treatment
Glutathione present in complex.
Reported limits
Soaking concentration, duration and full refinement methods were not retrieved from SI.
Methods and source locations

Compound reported in the paper: HPGDS inhibitor 1; Compound label in the paper: 8

Evidence concerns the authors’ compound 8, without Adooq lot validation or salt equivalence.

Table 2; Figure 5 and crystallography paragraph

Cocrystal refinement: Compound soaked into preformed crystals. — Figure 5 and crystallography paragraph

HPGDS inhibitor 1 In Vivo Studies

In allergic sheep, compound 8 reduced the late airway response and prevented subsequent hyperresponsiveness, while the early response was unchanged (2 sheep/group). [1]

Allergic sheep airway responses

Animal study · Antigen-responsive allergic sheep [1]

Late airway responses were reduced, with no early-phase effect; carbachol hyperresponsiveness was prevented.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Late airway responseMaximum inhibition 86%[1]
Pre/post antigen carbachol PC400 in drug trialp value p = 0.89[1]

Conditions shared by the study groups

Frequency
Bolus + infusion (Figure 7)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Compound 8 versus vehicle
1 mg/ml as labeled in Figures 7–8; administered mass dose unavailable.
Vehicle trial in the same animalsLate response and subsequent hyperresponsiveness attenuated; early response unchanged.[1]
Compound 8 versus vehicle
Model: Allergic sheep; same animals in drug and vehicle trials
Reported limits: Route, infusion rate, delivered mass dose, vehicle composition and trial spacing not given in the retrieved main text.
Methods and source locations

Compound reported in the paper: HPGDS inhibitor 1; Compound label in the paper: 8

Evidence concerns the authors’ compound 8, without Adooq lot validation or salt equivalence.

Figures 7–8; sheep-results paragraph; note 27

Late airway response: Lung resistance versus vehicle; 2 sheep/group. — Figure 7 and sheep-results paragraph

Pre/post antigen carbachol PC400 in drug trial: PC400 is carbachol concentration increasing pulmonary resistance by 400%. — Figure 8 caption and note 27

Compound 8 versus vehicle · Figures 7–8 and preceding sheep-results paragraph

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1033836-12-2
Applications HPGDS inhibitor
Formula C19H19F4N3O
Molecular Weight 381.37
SMILES
C1CN(CCC1NC(=O)C2=CN=C(C=C2)C3=CC(=CC=C3)F)CC(F)(F)F

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

HPGDS inhibitor 1 Research References

  1. [1] Carron CP, Trujillo JI, Olson KL, et al. Discovery of an Oral Potent Selective Inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS). ACS Medicinal Chemistry Letters (2010). PMID: 24900177 DOI: 10.1021/ml900025z Source material

Publications

1 publication citing this product

  1. Beixian Zhou, .et al. , Chin Med, 2023, Oct 27;18(1):139 PMID: 37891648

Added to your cart

View Cart Checkout
Loading...